Orphazyme A/S (ORPH) experienced an increase of 13.73% in premarket. However, the last trading session closed at $2.04 with a decrease of 1.45%.
Planned NDA Resubmission for Arimoclomol – What’s up?
On 11th February 2022, ORPH updated regarding the planned NDA Resubmission for Arimoclomol. This drug is used for the treatment of Niemann-Pick disease type C. Moreover, the next step in determining a possible route to resubmitting the NDA to the FDA is to request a Type C Meeting. Furthermore, NPC is a unique neurological disorder for which there are currently no approved treatments in the U. S., and therefore the company plans to continue the discussions with the Agency as they work to get arimoclomol approved in the US for this dreadful condition.
Nomination of Kim Stratton – More About it
Centogene (CNTG) announced on 1st February 2022 that Kim Stratton has been nominated as the chief executive officer. Mrs. Stratton will now drive CENTOGENE’s crucial strategic evolution on its road to maximum stakeholder value creation in her new capacity as CEO. Dr. Andrin Oswald, the Company’s Chief Executive Officer, and Managing Director quit his job to concentrate on his rehabilitation, prompting this nomination.
Moreover, Dr. Oswald took a medical leave of absence on December 20, 2021, as reported by the Company. While Dr. Oswald is on the mend, it will take some time, thus he has opted to hand over the CEO post to Kim Stratton, after consulting and agreeing with the Company’s supervisory board. Dr. Oswald will continue to serve as an advisor to CENTOGENE to guarantee a smooth change of leadership.
With Kim Stratton as the Chief Executive Officer, the company is very excited to create and execute the business possibilities. In addition, Kim is a powerful executive with extensive knowledge of rare diseases gained through her previous responsibilities in the pharmaceutical sector. Lastly, the company is excited to collaborate with Kim and translate the next phases of the plan into value for patients and stakeholders.